SCHEMBL14718637

SCHEMBL14718637

O=COCCSc1ccccc1[N+](=O)[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
APOBEC3G Q9HC16 2/20 0.41
POLB P06746 1/20 0.41
APOBEC3A P31941 1/20 0.41
MCL1 Q07820 1/20 0.41
CRBN Q96SW2 1/20 0.40
ALDH1A1 P00352 6/20 0.39
MAPT P10636 5/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALPG P10696 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11453241 0.79 ALDH1A1 (0.47) PDE7ASMN1; SMN2NPC1RECQLRAB9A
SCHEMBL12894151 0.77 PTGS2 (0.48) PDE7ASMN1; SMN2NPC1RECQLRAB9A
SCHEMBL14719084 0.77 ALDH1A1 (0.45) SMN1; SMN2NPC1RECQLRAB9APOLB
SCHEMBL8324749 0.76 ALDH1A1 (0.50) PDE7ASMN1; SMN2NPC1RECQLRAB9A
SCHEMBL7458037 0.76 CA2 (0.57) PDE7ASMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL7764834 0.76 MEN1 (0.50) PDE7ASMN1; SMN2MEN1KMT2AAPOBEC3G
SCHEMBL12919992 0.74 ALDH1A1 (0.43) PDE7ASMN1; SMN2NPC1RECQLRAB9A
SCHEMBL1967927 0.74 ALDH1A1 (0.53) SMN1; SMN2NPC1RECQLRAB9AKMT2A
SCHEMBL7293883 0.73 PDE7A (0.53) PDE7ASMN1; SMN2NPC1RECQLRAB9A
SCHEMBL8973221 0.73 PTGS2 (0.49) PDE7ASMN1; SMN2MEN1KMT2AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130052690-A1 PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-02-28 US claimed
US-20130310269-A1 HOT-START DIGITAL PCR SO AUSTIN (US) 2013-11-21 US disclosed
US-20130052690-A1 PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP SAMSUNG ELECTRONICS CO., LTD. (KR) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052690-A1 PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP POLL, POLRMT, POLN PDE7A 3056/4885SMN1; SMN2 3252/4885NPC1 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.